CTLA4 and neoplasm: LAG-3 staining of lymphocytes was observed in 43 baseline tumor specimens (81%, n = 43/53) of patients treated with combination anti-LAG-3 + anti-PD-1 ± anti-CTLA-4 immunotherapy.